A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With FGFR 1, 2, 3, or 4 Genetic Alterations

Trial Profile

A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With FGFR 1, 2, 3, or 4 Genetic Alterations

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs PRN 1371 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Principia Biopharma
  • Most Recent Events

    • 21 Nov 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 21 Nov 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
    • 03 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top